Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BMEA Biomea Fusion	$1.73 +2.4%	$1.90	$1.29 ▼ $13.07	$100.57M	-0.14	775,153 shs	356,703 shs
DRRX DURECT	$1.91 +0.5%	$0.97	$0.48 ▼ $2.64	$59M	0.83	2.94 million shs	537,102 shs
GELS Gelteq	$1.33 -6.3%	$1.80	$0.77 ▼ $5.50	$13.40M	N/A	114,555 shs	42,781 shs
ICCC ImmuCell	$6.10 -9.2%	$6.53	$3.34 ▼ $7.60	$60.73M	0.3	13,152 shs	32,969 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BMEA Biomea Fusion	-1.74%	+3.68%	-5.06%	+11.18%	-68.99%
DRRX DURECT	0.00%	+1.06%	+258.36%	+201.54%	+42.86%
GELS Gelteq	0.00%	-10.13%	-17.92%	-25.65%	+141,999,900.00%
ICCC ImmuCell	+2.91%	+9.45%	+7.35%	+27.51%	+90.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BMEA Biomea Fusion	3.6559 of 5 stars	4.6	3.0	0.0	0.0	1.9	2.5	0.6
DRRX DURECT	1.8512 of 5 stars	0.0	5.0	0.0	4.4	3.1	0.0	0.0
GELS Gelteq	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	0.4072 of 5 stars	0.0	5.0	0.0	0.0	1.1	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BMEA Biomea Fusion	3.17	Buy	$16.80	871.10% Upside
DRRX DURECT	2.00	Hold	N/A	N/A
GELS Gelteq	0.00	N/A	N/A	N/A
ICCC ImmuCell	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest GELS, BMEA, DRRX, and ICCC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$9.00 ➝ $7.00
8/6/2025	BMEA Biomea Fusion	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$30.00 ➝ $10.00
8/6/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
8/5/2025	BMEA Biomea Fusion	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/29/2025	DRRX DURECT	Northland Capmk Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/21/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/16/2025	BMEA Biomea Fusion	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$22.00 ➝ $9.00
6/24/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/13/2025	BMEA Biomea Fusion	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/3/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00
6/2/2025	BMEA Biomea Fusion	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	$0.46 per share	N/A
DRRX DURECT	$2.03M	29.21	N/A	N/A	$0.11 per share	17.36
GELS Gelteq	$100K	125.55	N/A	N/A	$1.30 per share	1.02
ICCC ImmuCell	$26.49M	2.08	$0.06 per share	104.51	$3.09 per share	1.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BMEA Biomea Fusion	-$138.43M	-$3.03	0.00	N/A	N/A	N/A	-243.95%	-140.74%	N/A
DRRX DURECT	-$8.32M	-$0.10	N/A	N/A	N/A	-96.19%	-259.16%	-71.78%	N/A
GELS Gelteq	-$2.33M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	-$2.16M	$0.19	35.37	∞	N/A	6.23%	6.37%	3.91%	N/A

Latest GELS, BMEA, DRRX, and ICCC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ICCC ImmuCell	N/A	$0.06	N/A	$0.06	N/A	$6.45 million
8/12/2025	Q2 2025	DRRX DURECT	-$0.13	-$0.07	+$0.06	-$0.07	$0.32 million	$0.45 million
8/5/2025	Q2 2025	BMEA Biomea Fusion	-$0.59	-$0.51	+$0.08	-$0.51	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BMEA Biomea Fusion	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	N/A	N/A	N/A	N/A	N/A
GELS Gelteq	N/A	N/A	N/A	N/A	N/A
ICCC ImmuCell	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BMEA Biomea Fusion	N/A	3.68	3.68
DRRX DURECT	N/A	0.98	1.22
GELS Gelteq	N/A	0.79	N/A
ICCC ImmuCell	0.30	4.12	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BMEA Biomea Fusion	96.72%
DRRX DURECT	28.03%
GELS Gelteq	N/A
ICCC ImmuCell	13.47%

Insider Ownership

Company	Insider Ownership
BMEA Biomea Fusion	18.42%
DRRX DURECT	3.20%
GELS Gelteq	N/A
ICCC ImmuCell	5.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BMEA Biomea Fusion	50	59.51 million	30.65 million	Optionable
DRRX DURECT	80	31.05 million	30.05 million	Optionable
GELS Gelteq	N/A	9.44 million	N/A	N/A
ICCC ImmuCell	70	9.04 million	8.53 million	Not Optionable

GELS, BMEA, DRRX, and ICCC Headlines

Recent News About These Companies

ImmuCell Corporation (ICCC) Q2 2025 Earnings Call Transcript

August 15 at 12:14 PM | seekingalpha.com

ImmuCell Announces Unaudited Financial Results forÂ the Quarter Ended June 30, 2025

August 14 at 4:14 PM | globenewswire.com

ImmuCell (NASDAQ:ICCC) Shares Pass Above 200 Day Moving Average - Should You Sell?

August 14 at 4:27 AM | marketbeat.com

ImmuCell Corporation: ImmuCell Announces Bank Debt Refinancing

August 13 at 12:41 PM | finanznachrichten.de

ImmuCell Refinances Debt with Maine Community Bank

August 13 at 2:20 AM | msn.com

ImmuCell Announces Bank Debt Refinancing

August 12 at 4:05 PM | globenewswire.com

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025

August 7, 2025 | globenewswire.com

ImmuCell (NASDAQ:ICCC) Stock Passes Above 200 Day Moving Average - Should You Sell?

July 29, 2025 | marketbeat.com

ImmuCell Upgraded to Outperform on Sales Surge & FDA Upside

July 22, 2025 | zacks.com

ImmuCell (NASDAQ:ICCC) Stock Price Passes Above 200 Day Moving Average - Here's What Happened

July 19, 2025 | marketbeat.com

ImmuCell Corporation Reports 18% Increase in Q2 2025 Sales Results

July 9, 2025 | quiverquant.comQ

ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025

July 9, 2025 | globenewswire.com

ImmuCell Embarks on CEO Succession Planning Process

June 25, 2025 | globenewswire.com

ImmuCell stock soars to 52-week high, touches $7 mark

June 5, 2025 | investing.com

ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders

June 5, 2025 | globenewswire.com

ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains

May 19, 2025 | zacks.com

ImmuCell Q2 2025 slides: sales momentum continues as Re-Tain awaits FDA approval

May 16, 2025 | investing.com

Earnings call transcript: ImmuCell’s Q1 2025 revenue hits record, stock surges

May 16, 2025 | investing.com

ImmuCell Corporation (NASDAQ:ICCC) Q1 2025 Earnings Call Transcript

May 16, 2025 | msn.com

ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

ImmuCell signals capacity expansion to $30M+ and launches new First Defense formats as backlog declines

May 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS, BMEA, DRRX, and ICCC Company Descriptions

Biomea Fusion NASDAQ:BMEA

$1.73 +0.04 (+2.37%)

Closing price 04:00 PM Eastern

Extended Trading

$1.70 -0.03 (-2.02%)

As of 05:44 PM Eastern

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.

DURECT NASDAQ:DRRX

$1.91 +0.01 (+0.53%)

As of 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Gelteq NASDAQ:GELS

$1.33 -0.09 (-6.34%)

As of 04:00 PM Eastern

Gelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.

ImmuCell NASDAQ:ICCC

$6.10 -0.62 (-9.23%)

Closing price 03:59 PM Eastern

Extended Trading

$6.21 +0.11 (+1.80%)

As of 04:10 PM Eastern

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time